These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 32105179)

  • 21. The Canadian methotrexate and etanercept outcome study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritis.
    Pope JE; Haraoui B; Thorne JC; Vieira A; Poulin-Costello M; Keystone EC
    Ann Rheum Dis; 2014 Dec; 73(12):2144-51. PubMed ID: 23979914
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness analysis of etanercept plus methotrexate vs triple therapy in treating Chinese rheumatoid arthritis patients.
    Shi ZC; Fei HP; Wang ZL
    Medicine (Baltimore); 2020 Jan; 99(3):e16635. PubMed ID: 32011430
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
    Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patterns of medication utilization and costs associated with the use of etanercept, adalimumab, and ustekinumab in the management of moderate-to-severe psoriasis.
    Feldman SR; Zhao Y; Navaratnam P; Friedman HS; Lu J; Tran MH
    J Manag Care Spec Pharm; 2015 Mar; 21(3):201-9. PubMed ID: 25726029
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reduction of methotrexate and glucocorticoids use after the introduction of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis in daily practice based on the IORRA cohort.
    Shimizu Y; Tanaka E; Inoue E; Shidara K; Sugimoto N; Seto Y; Nakajima A; Momohara S; Taniguchi A; Yamanaka H
    Mod Rheumatol; 2018 May; 28(3):461-467. PubMed ID: 28880684
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-world Comparative Effectiveness of Methotrexate-based Combinations for Rheumatoid Arthritis: A Retrospective Cohort Study.
    Huang Y; Agarwal SK; Chen H; Chatterjee S; Johnson ML; Aparasu RR
    Clin Ther; 2023 Sep; 45(9):e177-e186. PubMed ID: 37573225
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Uttley L; Bermejo I; Ren S; Martyn-St James M; Wong R; Scott DL; Young A; Stevenson M
    Pharmacoeconomics; 2018 Sep; 36(9):1063-1072. PubMed ID: 29546668
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.
    Tzanetakos C; Tzioufas A; Goules A; Kourlaba G; Theodoratou T; Christou P; Maniadakis N
    Rheumatol Int; 2017 Sep; 37(9):1441-1452. PubMed ID: 28523420
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and Treatment Costs of Monotherapy with bDMARDs in the Treatment of Rheumatoid Arthritis in Patients Intolerant to or Inappropriate to Continue Treatment with Methotrexate.
    Batticciotto A; Ravasio R; Riva M; Sarzi-Puttini P
    Adv Ther; 2016 Aug; 33(8):1360-73. PubMed ID: 27376373
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness analysis of tofacitinib compared with adalimumab and etanercept in the treatment of severe active rheumatoid arthritis; Iranian experience.
    Fatemi B; Rezaei S; Taheri S; Peiravian F
    Expert Rev Pharmacoecon Outcomes Res; 2021 Aug; 21(4):775-784. PubMed ID: 33043757
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Etanercept is effective as monotherapy or in combination with methotrexate in rheumatoid arthritis: subanalysis of an observational study.
    Gaubitz M; Göttl KH; Behmer O; Lippe R; Meng T; Löschmann PA
    Clin Rheumatol; 2017 Sep; 36(9):1989-1996. PubMed ID: 28756532
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry.
    Weaver AL; Lautzenheiser RL; Schiff MH; Gibofsky A; Perruquet JL; Luetkemeyer J; Paulus HE; Xia HA; Leff JA;
    Curr Med Res Opin; 2006 Jan; 22(1):185-98. PubMed ID: 16393444
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment Patterns, Direct Cost of Biologics, and Direct Medical Costs for Rheumatoid Arthritis Patients: A Real-world Analysis of Nationwide Japanese Claims Data.
    Sugiyama N; Kawahito Y; Fujii T; Atsumi T; Murata T; Morishima Y; Fukuma Y
    Clin Ther; 2016 Jun; 38(6):1359-1375.e1. PubMed ID: 27101816
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radiographic and clinical outcomes following etanercept monotherapy in Japanese methotrexate-naïve patients with active rheumatoid arthritis.
    Takeuchi T; Miyasaka N; Pedersen R; Sugiyama N; Hirose T
    Mod Rheumatol; 2020 Mar; 30(2):259-268. PubMed ID: 30836801
    [No Abstract]   [Full Text] [Related]  

  • 35. Etanercept in combination with conventional disease-modifying antirheumatic drugs (DMARDs) in the treatment of rheumatoid arthritis patients intolerant to methotrexate.
    Koyama Y; Shiraishi H; Ohta T; Uchino A
    Mod Rheumatol; 2012 Feb; 22(1):100-8. PubMed ID: 21706263
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study.
    Detert J; Bastian H; Listing J; Weiß A; Wassenberg S; Liebhaber A; Rockwitz K; Alten R; Krüger K; Rau R; Simon C; Gremmelsbacher E; Braun T; Marsmann B; Höhne-Zimmer V; Egerer K; Buttgereit F; Burmester GR
    Ann Rheum Dis; 2013 Jun; 72(6):844-50. PubMed ID: 22739990
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis: Modeling the Cost of Treatment Strategies in the United States.
    Claxton L; Jenks M; Taylor M; Wallenstein G; Mendelsohn AM; Bourret JA; Singh A; Moynagh D; Gerber RA
    J Manag Care Spec Pharm; 2016 Sep; 22(9):1088-102. PubMed ID: 27579831
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA.
    Chastek B; Chen CI; Proudfoot C; Shinde S; Kuznik A; Wei W
    Adv Ther; 2017 Nov; 34(11):2422-2435. PubMed ID: 29039054
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Initial Experience With Tofacitinib in Clinical Practice: Treatment Patterns and Costs of Tofacitinib Administered as Monotherapy or in Combination With Conventional Synthetic DMARDs in 2 US Health Care Claims Databases.
    Harnett J; Curtis JR; Gerber R; Gruben D; Koenig A
    Clin Ther; 2016 Jun; 38(6):1451-1463. PubMed ID: 27112534
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy.
    van der Heijde D; Burmester G; Melo-Gomes J; Codreanu C; Mola EM; Pedersen R; Freundlich B; Chang DJ;
    Ann Rheum Dis; 2008 Feb; 67(2):182-8. PubMed ID: 17728331
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.